News
Stay Up-To-Date on NEXT Oncology
- All
- NEXT Oncology Blog
- NEXT Oncology News
- Press Releases
Phase 1 Studies of Novel Autologous CAR T-Cell Therapies Show Promise in GI Cancers
Two phase 1 studies report encouraging findings with use of novel autologous CAR T-cell therapies in gastrointestinal (GI) malignancies. Read More
NEXT Oncology Moves Cancer Research Forward
NEXT Oncology, a Phase 1 Clinical Trial organization with six locations around the world, played a significant role in moving cancer research forward at the recent American Society of Clinical ...
Novel IO Approaches Demonstrate High pCR Rates in the Neoadjuvant Setting, Questioning the Need for Surgery in Certain Patients With CRC
Despite recent advances in immunotherapy, certain subtypes of colorectal cancer, such as those that are MSI-high, dMMR of TMB-H, remain a treatment challenge. Moreover, the optimal therapeutic approach for colorectal ...
Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
NEW HAVEN, Conn., May 29, 2024 /PRNewswire/ — Biohaven Ltd. (NYSE: BHVN) (Biohaven), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of ...
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced first clinical data from its Phase 1 dose escalation cohort of CLN-619 in combination with ...
NEXT Oncology and OncoBay Clinical Collaborate on Six Phase 1 Clinical Trials
FOR IMMEDIATE RELEASE DATE: April 22, 2024 Contact: Lisa Owens, 210-601-6647 (SAN ANTONIO, TX and RALEIGH, NC) April 22, 2024 ––NEXT Oncology, a Phase 1 Clinical Trial organization with six ...
Announcing the 2024 Health Care Heroes
“We are so proud of our founder and CEO, Dr. Anthony Tolcher” for being named one of San Antonio’s Health Care Heroes by the San Antonio Business Journal. We will ...
Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series
Biliary tract cancer (BTC) refers to several cancers of the biliary system, and covers a range of invasive adenocarcinomas, including intrahepatic cholangiocarcinoma (iCCA), extrahepatic cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma. ...
D2M Biotherapeutics Announces First Patient Dosed in A Phase 1 Study Evaluating DM919, a Novel MICA/B Antibody for Treating Patients with Advanced Solid Tumors
D2M Biotherapeutics, Inc. (D2M), a clinical stage biotech company focused on developing innovative therapies in treating Immunological-Inflammatory diseases and cancers, today announced that the first patient had been dosed in ...
Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate in a ...